



February 12, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Press release on unaudited Financial Results for the quarter ended December 31, 2024

We are enclosing herewith the Press Release, regarding the unaudited Financial Results for quarter ended December 31, 2024, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record.

Thanking you.
Yours faithfully,

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary



Procter & Gamble Health Announces Second Quarter Results

PAT up 26% for the quarter ended December 31, 2024

Mumbai, February 12, 2025: Procter & Gamble Health Limited today announced its financial results for the quarter ended December 31, 2024. The Company reported sales of ₹ 304 crores, flat versus a year ago. The Profit After Tax (PAT) for the quarter was ₹91 crores, up 26% versus a year ago. Excluding the one-time item in the base year, the operational Profit After Tax (PAT) was up 13% versus a year ago.

Commenting on the results, **Mr. Milind Thatte, Managing Director, P&G Health India**, said, *“This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.”*

The Board has declared an interim dividend of ₹80 per equity share for the Financial Year 2024-25. The record date for the dividend will be February 21, 2025.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS:

Media Contacts - Procter & Gamble Health Limited:

Paromita Kundu | kundu.p.1@pg.com

Agency Contact – SPAG FINN Partners

Sarah Rajan | sarah.rajan@finnpartners.com

Jyotsana Saluja | Jyotsana.saluja@finnpartners.com